What is Wedbush’s Forecast for VERA FY2029 Earnings?

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at Wedbush issued their FY2029 earnings per share estimates for shares of Vera Therapeutics in a report released on Thursday, February 27th. Wedbush analyst L. Chico forecasts that the company will earn $2.16 per share for the year. Wedbush has a “Neutral” rating and a $38.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics’ FY2029 earnings at $2.16 EPS.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.11.

Several other research firms have also recently weighed in on VERA. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. JPMorgan Chase & Co. raised their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. Wells Fargo & Company assumed coverage on Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target for the company. Finally, Guggenheim upped their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Vera Therapeutics currently has an average rating of “Buy” and an average target price of $65.11.

Vera Therapeutics Trading Up 5.9 %

Shares of VERA opened at $29.41 on Friday. The firm has a market cap of $1.86 billion, a P/E ratio of -11.27 and a beta of 1.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a 1 year low of $25.99 and a 1 year high of $51.61. The company has a 50 day simple moving average of $36.00 and a two-hundred day simple moving average of $40.35.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in shares of Vera Therapeutics in the 4th quarter worth about $56,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Vera Therapeutics by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,106 shares of the company’s stock worth $3,388,000 after purchasing an additional 18,532 shares during the period. Woodline Partners LP lifted its stake in Vera Therapeutics by 20.1% in the fourth quarter. Woodline Partners LP now owns 1,202,466 shares of the company’s stock worth $50,852,000 after purchasing an additional 201,573 shares during the last quarter. Vestal Point Capital LP purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at approximately $45,462,000. Finally, Thornburg Investment Management Inc. grew its stake in shares of Vera Therapeutics by 91.1% during the fourth quarter. Thornburg Investment Management Inc. now owns 59,004 shares of the company’s stock valued at $2,495,000 after buying an additional 28,124 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the sale, the chief executive officer now owns 85,942 shares in the company, valued at approximately $3,701,521.94. This represents a 16.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold 52,500 shares of company stock valued at $2,305,625 in the last ninety days. Insiders own 21.70% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.